Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
August 07 2018 - 4:05PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced its participation at the
2018 Wedbush PacGrow Healthcare Conference. Troy Wilson, Ph.D.,
J.D., President and Chief Executive Officer, is scheduled to
present an overview of the company on Tuesday, August 14, 2018 at
12:45 p.m. ET / 9:45 a.m. PT. The conference will be held from
August 14-15, 2018 in New York.
A live audio webcast of the presentation will be available in
the Investors section of Kura’s website at www.kuraoncology.com,
with an archived replay available for 30 days following the
event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s lead drug candidate is tipifarnib, a
farnesyl transferase inhibitor, which is currently being studied in
multiple Phase 2 clinical trials in solid tumor and hematologic
indications. Kura is planning to initiate a registration-directed
trial of tipifarnib in HRAS mutant head and neck squamous cell
carcinomas later this year. Kura’s pipeline also includes KO-947,
an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and
KO-539, a menin-MLL inhibitor, currently in preclinical
development. For additional information about Kura Oncology, please
visit the company’s website at www.kuraoncology.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “believes,” “anticipates,” “plans,” “expects,” “intends,”
“will,” “goal,” “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Kura Oncology’s current expectations and
involve assumptions that may never materialize, or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with Kura Oncology’s business
and finances in general, and the other risks described in Kura
Oncology’s periodic and other filings with the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Kura Oncology
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate CommunicationsKura Oncology, Inc.(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024